Zobrazeno 1 - 10
of 87
pro vyhledávání: '"David J Gordon"'
Autor:
Jordan L Kohlmeyer, David J Gordon, Munir R Tanas, Varun Monga, Rebecca D Dodd, Dawn E Quelle
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 8, p 3018 (2020)
Sarcomas represent one of the most challenging tumor types to treat due to their diverse nature and our incomplete understanding of their underlying biology. Recent work suggests cyclin-dependent kinase (CDK) pathway activation is a powerful driver o
Externí odkaz:
https://doaj.org/article/0964510281f54fceb8d7cc183bcb901c
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Novel therapeutic approaches are needed for the treatment of Ewing sarcoma tumors. We previously identified that Ewing sarcoma cell lines are sensitive to drugs that inhibit protein translation. However, translational and therapeutic approaches to in
Externí odkaz:
https://doaj.org/article/7f37a116e14143109f12ef468ee9eca5
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 16, p 8595 (2024)
Ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis of deoxyribonucleotides and the target of multiple chemotherapy drugs, including gemcitabine. We previously identified that inhibition of RNR in Ewing sarcoma tumors upregula
Externí odkaz:
https://doaj.org/article/44f2127aeecf4e698c2b3617c6715ff1
Autor:
Wade R. Gutierrez, Amanda Scherer, Jeffrey D. Rytlewski, Emily A. Laverty, Alexa P. Sheehan, Gavin R. McGivney, Qierra R. Brockman, Vickie Knepper-Adrian, Grace A. Roughton, Dawn E. Quelle, David J. Gordon, Varun Monga, Rebecca D. Dodd
Publikováno v:
JCI Insight, Vol 7, Iss 22 (2022)
The DNA methyltransferase inhibitor decitabine has classically been used to reactivate silenced genes and as a pretreatment for anticancer therapies. In a variation of this idea, this study explores the concept of adding low-dose decitabine (DAC) fol
Externí odkaz:
https://doaj.org/article/f1f2ba4470e1443796a237d00e963599
Supplementary Figure 8 shows the effect of gemcitabine on the phosphorylation of 4E-BP1 in non-Ewing sarcoma cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b6442023724d1d12af75561abe880f
https://doi.org/10.1158/1535-7163.22504360
https://doi.org/10.1158/1535-7163.22504360
Autor:
Garry R. Buettner, Joseph J. Cullen, Stacia L. Koppenhafer, David J. Gordon, Juan Du, Brett A. Wagner, Adrienne R. Gibson, Claire M. Doskey, Visarut Buranasudja
The clinical potential of pharmacologic ascorbate (P-AscH−; intravenous delivery achieving mmol/L concentrations in blood) as an adjuvant in cancer therapy is being reevaluated. At mmol/L concentrations, P-AscH− is thought to exhibit anticancer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df5135080f44dc08255e9db4fd36b519
https://doi.org/10.1158/1541-7786.c.6541251
https://doi.org/10.1158/1541-7786.c.6541251
Supplementary Figure 6 shows the effect of RRM2 knockdown in Ewing sarcoma cells, as well as RT-qPCR data for cells treated with AZD1775 and LY2603618.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60a0c690344af9a0d67bb6cd1b68ec51
https://doi.org/10.1158/1541-7786.22512580.v1
https://doi.org/10.1158/1541-7786.22512580.v1
Supplementary Figure 2 shows detection of protein synthesis using puromycin labeling.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443524b26ac4c3d552b7c00460f94829
https://doi.org/10.1158/1535-7163.22504381.v1
https://doi.org/10.1158/1535-7163.22504381.v1
Supplementary Figure 6 shows the effect of drug treatments on mice weights in the xenograft experiments.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ed9e0767183a4cee3938c6b56698ee
https://doi.org/10.1158/1535-7163.22504366.v1
https://doi.org/10.1158/1535-7163.22504366.v1
Supplementary Figure 7 shows the effects of gemcitabine on protein synthesis in U2OS and RPE-tert cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16e384bcc8bb3dafda6317e02fb1cde7
https://doi.org/10.1158/1535-7163.22504363.v1
https://doi.org/10.1158/1535-7163.22504363.v1